Pay in 4 interest-free payments of $7.49 Learn more
Ships within 48 hours · Estimated delivery Aug 28 - Sep 2
Some individuals experience severe nausea, vomiting, or gastrointestinal distress on semaglutide that does not resolve with dose adjustments
Injection-site reactions: redness, swelling, or irritation (generally mild and transient) [11]
Retatrutide Phase 2: 17.5% body weight NEJM 2023 Cardiovascular Metabolic Cardio-Metabolic Research GLP-1 class reduces cardiovascular events
Important factors affecting GLP-1 market demand and take-up include: The need for better long-term data on the safety and efficacy of use for the designated indications The rapidly expanding list of potential new indications for the drugs, including chronic kidney disease, broader cardiovascular risk reduction, metabolic liver disease, and Alzheimer's disease The number of similar drugs in the development pipeline Price point versus competition, which affects affordability and insurance coverage Marketing efforts of the manufacturers, supply and distribution constraints
